NeuroVigil Begins Brain Research Initiatives

NeuroVigil Inc. is making moves in brain research as it strikes a multi-year deal to help an unnamed pharmaceutical company as well as an alliance with the University of Basel in Switzerland to tackle Rett Syndrome, a lethal neurodevelopmental disorder that affects girls almost exclusively.    

NeuroVigil’s proprietary suite of software algorithms and portable brain activity monitors was launched commercially in 2009 and now is a prevailing model for early central nervous system pharmaceutical research. The commercial agreement, five years in development, will greatly expand the pharma firm’s research and development capabilities by gaining access to high-resolution and high-throughput data while augmenting NeuroVigil’s exclusive biomarker databases. NeuroVigil will retain all rights to its data and any biomarkers discovered by either party and will not advise the pharmaceutical company on the pharmacological applications of its compounds. The uncapped agreement is unrestricted and both parties remain free to collaborate with other parties.

“This new collaboration heralds an advancement for both companies—to discover and promote innovative methods to monitor disease and ultimately improve human health,” said Philip Low, Ph.D., founder, chairman, CEO and chief scientific officer of NeuroVigil.

NeuroVigil develops noninvasive wireless brain recording technology with advanced computational analysis techniques applied exclusively on human data. The firm has active programs in neuroengineering at its La Jolla, Calif. headquarters, and in computational neuroscience at its NASA satellite laboratory in Silicon Valley.